Short-term rosuvastatin therapy prevents contrast-induced acute kidney injury in female patients with diabetes and chronic kidney disease: A subgroup analysis of the TRACK-D study

Journal of Thoracic Disease

Volumn 8, Issue 5, 2016, Pages 1000-1006

  Li, Jing ^a   Li, Yi ^a   Xu, Biao ^b   Jia, Guoliang ^c   Guo, Tao ^d   Wang, Dongmei ^e   Xu, Kai ^a   Deng, Jie ^a   Han, Yaling ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c Dongguan Kanghua Hospital   (China)

^d KUNMING MEDICAL UNIVERSITY   (China)

^e Shijiazhuang Peace Hospital   (China)

Author keywords

Chronic kidney disease (CKD); Contrast medium; Diabetes; Female; Kidney injury; Statin

Indexed keywords

CONTRAST MEDIUM; ROSUVASTATIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEART FAILURE; HEMOFILTRATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; RENAL PROTECTION; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SHORT COURSE THERAPY;

EID: 84964931456     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.21037/jtd.2016.03.26     Document Type: Article

References (21)

1. Brown JR, DeVries JT, Piper WD, et al. Serious renal dysfunction after percutaneous coronary interventions can be predicted. Am Heart J 2008;155:260-6.
2. Maioli M, Toso A, Gallopin M, et al. Preprocedural score for risk of contrast-induced nephropathy in elective coronary angiography and intervention. J Cardiovasc Med (Hagerstown) 2010;11:444-9.
3. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393-9.
4. Watabe H, Sato A, Hoshi T, et al. Association of contrastinduced acute kidney injury with long-term cardiovascular events in acute coronary syndrome patients with chronic kidney disease undergoing emergent percutaneous coronary intervention. Int J Cardiol 2014;174:57-63.
5. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004;93:1515-9.
6. Chen SL, Zhang J, Yei F, et al. Clinical outcomes of contrastinduced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine. Int J Cardiol 2008;126:407-13.
7. McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006;98:27K-36K.
8. McCullough PA. Acute kidney injury with iodinated contrast. Crit Care Med 2008;36:S204-11.
9. Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008;101:279-85.
10. Lucreziotti S, Centola M, Salerno-Uriarte D, et al. Female gender and contrast-induced nephropathy in primary percutaneous intervention for ST-segment elevation myocardial infarction. Int J Cardiol 2014;174:37-42.
11. Han Y, Zhu G, Han L, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 2014;63:62-70.
12. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937-44.
13. Andò G, de Gregorio C, Morabito G, et al. Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced acute kidney injury risk in patients undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2014;7:465-72.
14. Rezaeian S, Moghimbeigi A, Esmailnasab N. Gender differences in risk factors of congenital hypothyroidism: an interaction hypothesis examination. Int J Endocrinol Metab 2014;12:e13946.
15. Iakovou I, Dangas G, Mehran R, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003;15:18-22.
16. Park K, Chung WY, Seo JB, et al. The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial. Trials 2010;11:122.
17. Kiski D, Stepper W, Breithardt G, et al. Impact of female gender on frequency of contrast medium-induced nephropathy: post hoc analysis of dialysis versus diuresis trial. J Womens Health (Larchmt) 2010;19:1363-8.
18. Mikkelsen AP, Lindhardsen J, Lip GY, et al. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost 2012;10:1745-51.
19. Mueller C, Buerkle G, Perruchoud AP, et al. Female sex and risk of contrast nephropathy after percutaneous coronary intervention. Can J Cardiol 2004;20:505-9.
20. Prasad PV, Epstein FH. Changes in renal medullary pO2 during water diuresis as evaluated by blood oxygenation level-dependent magnetic resonance imaging: effects of aging and cyclooxygenase inhibition. Kidney Int 1999;55:294-8.
21. Gottlieb DJ, Stone PJ, Sparrow D, et al. Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. Am J Respir Crit Care Med 1996;154:1290-5.